论文部分内容阅读
目的:观察马来酸罗格列酮对2型糖尿病大鼠血清糖基化终产物-肽(AGE-P)和单核细胞趋化蛋白-1(MCP-1)水平的影响。方法:腹腔注射小剂量链脲佐菌素结合高能量饲料制备2型糖尿病大鼠模型,分别接受马来酸罗格列酮、格列本脲治疗12周。运用流动注射分析法测定血清AGE-P,ELISA法测定血清MCP-1水平。结果:糖尿病大鼠血清AGE-P和MCP-1明显高于对照组,两者显著相关;药物治疗组血清AGE-P低于模型组但高于正常对照,罗格列酮组水平低于格列本脲组;罗格列酮组血清MCP-1低于模型组和格列本脲组。结论:糖尿病动物血清AGE-P和MCP-1升高,两者相互作用可能有助于糖尿病慢性并发症发生发展;降低血糖有助于降低血清AGE-P水平;罗格列酮具有超越降糖之外的降低血清AGE-P和MCP-1效应,可能具备更优的防治糖尿病慢性并发症作用。
Objective: To observe the effects of rosiglitazone maleate on the levels of serum aglycone (AGE) -peptide and monocyte chemoattractant protein-1 (MCP-1) in type 2 diabetic rats. Methods: A rat model of type 2 diabetes mellitus was prepared by intraperitoneal injection of low-dose streptozotocin combined with high energy feed. The rats were treated with rosiglitazone maleate and glibenclamide for 12 weeks respectively. Serum AGE-P levels were measured by flow injection analysis and serum MCP-1 levels were measured by ELISA. Results: The levels of AGE-P and MCP-1 in serum of diabetic rats were significantly higher than those of the control group, but the levels of AGE-P in the drug-treated group were lower than those in the normal control group and rosiglitazone group Benprofol group; rosiglitazone group serum MCP-1 lower than model group and glibenclamide group. CONCLUSIONS: AGE-P and MCP-1 are elevated in the serum of diabetic animals, and the interaction between the two may contribute to the development of chronic complications of diabetes. Lowering blood glucose will help to reduce serum AGE-P levels. Rosiglitazone may have more effects than hypoglycemic Outside the lower serum AGE-P and MCP-1 effect, may have better prevention and treatment of chronic complications of diabetes.